Methadone, Pierre Robin sequence and other congenital anomalies: case-control study

Brian Cleary, Maria Loane, Marie-Claude Addor, Ingeborg Barisic, HEK de Walle, Carlos Matias Dias, Miriam Gatt, Kari Klungsoyr, Bob McDonnell, Amanda Neville, Anna Pierini, Anke Rissmann, David Tucker, Oscar Zurriaga, Helen Dolk

Research output: Contribution to journalArticle

15 Downloads (Pure)

Abstract

Objective
Methadone is a vital treatment for women with opioid use disorder in pregnancy. Previous reports suggested an association between methadone exposure and Pierre Robin sequence (PRS), a rare craniofacial anomaly. We assessed the association between gestational methadone exposure and PRS.

Design/setting
This case-malformed control study used European Surveillance of Congenital Anomalies population-based registries in Ireland, the Netherlands, Italy, Switzerland, Croatia, Malta, Portugal, Germany, Wales, Norway and Spain, 1995–2011.

Patients
Cases included PRS based on International Classification of Disease (ICD), Ninth Edition-British Paediatric Association (BPA) code 75 603 or ICD, Tenth Edition-BPA code Q8708. Malformed controls were all non-PRS anomalies, excluding genetic conditions, among live births, fetal deaths from 20 weeks’ gestation and terminations of pregnancy for fetal anomalies. An exploratory analysis assessed the association between methadone exposure and other congenital anomalies (CAs) excluding PRS. Methadone exposure was ascertained from medical records and maternal interview.

Results
Among 87 979 CA registrations, there were 127 methadone-exposed pregnancies and 336 PRS cases. There was an association between methadone exposure and PRS (OR adjusted for registry 12.3, 95% CI 5.7 to 26.8). In absolute terms, this association reflects a risk increase from approximately 1–12 cases per 10 000 births. A raised OR was found for cleft palate (adjusted OR 5.0, 95% CI 2.7 to 9.2).

Conclusions
These findings suggest that gestational methadone exposure is associated with PRS. The association may be explained by unmeasured confounding factors. The small increased risk of PRS in itself does not alter the risk–benefit balance for gestational methadone use. The association with cleft palate, a more common CA, should be assessed with independent data.
Original languageEnglish
Pages (from-to)F1-F7
Number of pages7
JournalArchives of Disease in Childhood - Fetal and Neonatal Edition
Volume0
Issue number10.1136/archdischild-2019-316804
DOIs
Publication statusPublished - 22 Jun 2019

Keywords

  • Methadone
  • Congenital Anomalies
  • Pierre Robin
  • Birth Defects
  • Craniofacial anomaly
  • EUROCAT
  • opioid use disorder
  • cleft palate
  • methadone
  • Pierre Robin sequence

Fingerprint Dive into the research topics of 'Methadone, Pierre Robin sequence and other congenital anomalies: case-control study'. Together they form a unique fingerprint.

  • Cite this

    Cleary, B., Loane, M., Addor, M-C., Barisic, I., de Walle, HEK., Dias, C. M., Gatt, M., Klungsoyr, K., McDonnell, B., Neville, A., Pierini, A., Rissmann, A., Tucker, D., Zurriaga, O., & Dolk, H. (2019). Methadone, Pierre Robin sequence and other congenital anomalies: case-control study. Archives of Disease in Childhood - Fetal and Neonatal Edition, 0(10.1136/archdischild-2019-316804), F1-F7. https://doi.org/10.1136/archdischild-2019-316804